Browse Studies — Arctuva

Phase 3

A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome

This is a phase 3, double-blind, randomized, placebo-controlled, parallel group, adaptive, multicenter study planned to be conducted at multiple sites in North…

Venous MalformationsLymphatic MalformationsKlippel-Trenaunay Syndrome+1 more

Estimated

~$10 – $8,750

Kaken PharmaceuticalNCT07285005

Phase 2

A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment wit…

Lymphatic Malformations

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT05948943

Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+5 more

Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT06789913